The goal of this clinical trial is to assess the safety and efficacy of Human Placenta Mesenchymal Stem Cells Derived Exosomes in preventing early anastomosis leak in patients undergoing low anterior resection for rectal cancer. The main question it aims to answer are
Do Mesenchymal Stem Cell-Derived Exosomes prevent early anastomosis leak in patients undergoing low anterior resection for rectal cancer?
If there is a comparison group: Researchers will compare Mesenchymal Stem Cells Derived Exosomes to placebo to see if it can prevent early anastomotic leakage.
Participants will receive intraperitoneal Mesenchymal Stem Cells Derived Exosomes at the end of their surgery.
None
Patients who need emergency surgery (presenting with peritonitis or signs of obstruction)
Patients with apparent malnutrition or patients who have serum albumin levels of less than 3 g/dl
Patients who receive corticosteroids ( an equivalent dose of prednisolone 5 mg/day or more)
Patients with chronic pulmonary disease